Pemetrexed (Alimta®): A novel multitargeted antifolate agent

Expert Review of Anticancer Therapy

Volumn 3, Issue 2, 2003, Pages 145-156

  Adjei, Alex A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Antifolate; Pemetrexed; Solid tumors; Thymidylate synthase

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; DEXAMETHASONE; DIHYDROFOLATE REDUCTASE; DOCETAXEL; FLOXURIDINE; FLUOROURACIL; FOLIC ACID; FOLIC ACID ANTAGONIST; GEMCITABINE; IRINOTECAN; LOMETREXOL; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; PURINE; PYRIMIDINE; RALTITREXED; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BONE MARROW SUPPRESSION; BREAST CANCER; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME INHIBITION; FATIGUE; FOLATE METABOLISM; GRANULOCYTOPENIA; HEAD AND NECK CANCER; HUMAN; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MESOTHELIOMA; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; PURINE SYNTHESIS; PYRIMIDINE SYNTHESIS; RASH; REVIEW; SOLID TUMOR; THROMBOCYTOPENIA; UTERINE CERVIX CANCER; VITAMIN SUPPLEMENTATION; CELL CULTURE; NEOPLASM;

ANTINEOPLASTIC AGENTS; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; HUMANS; NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 85047688457     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.3.2.145     Document Type: Review

References (53)

1. Plunkett W, Huang P, Xu YZ et al. Gemcitabine: metabolism, mechanisms of action and self-potentiation. Semin. Oncol. 22, 3-10, (1995).
2. Shih C, Mendelsohn LG, Chen VJ, Schultz RM. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY-231514 (MTA). Adv. Enzyme Regul. 38, 135-152 (1998).
3. Taylor EC, Patel HH. Synthesis of pyrazolo(3,4,-d)pyrimidine analogues of the potent antitumor agent n-{4-(2-(2-amino-4 (3H)-oxo-7h-pyrrolo(2,3-d) pyrimidin-5-yl)ethyl)benz oyl}-l-glutamic acid (LY-231514). Tetrahedron Let. 48(37), 8089-8100 (1992).
4. Mendelsohn LG, Shih C, Chen VJ, Habeck LL, Gates SB, Shackelford KA. Enzyme inhibition, polyglutamation and the effect of LY-231514 (MTA) on purine biosynthesis. Semin. Oncol. 26(2, Suppl. 6), 42-47 (1999).
5. Rhee MS, Ryan TJ, Galivan J. Glutamyl hydrolase and the multitargeted antifolate LY-231514. Cancer Chemother. Pharmacol. 44, 427-432 (1999).
6. Schultz RM, Patel VF, Worzalla JF et al. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY-231514. Anticancer Res. 19(1), 437-443 (1991).
7. Schilsky RL. Antimetabolites. In: The Chemotherapy Source Book. Perry MC (Ed.). Williams & Wilkins, Baltimore, MD, USA. 301-315 (1992).
8. Grem JL. Fluorinated pyrimidines. In: Cancer Chemotherapy: Principles and Practice. Chabner BA, Collins JM (Eds). Lippincott, Philadelphia, PA, USA. 180-224 (1990).
9. Shih C, Chen VJ, Gossett LS et al. LY-231514, a pyrrolo(2,3-d)pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 57(6), 1116-2011 (1997).
10. Shih C, Thornton DE. Preclinical pharmacology studies and the clinical development of a novel multitargeted antifolate, MTA (LY-231514). In: Antifolate Drugs in Cancer Therapy. Jackman AL (Ed.). Humana Press, Totowa, NJ, USA. 183-201 (1999).
11. Woodland JM, Barnett CJ, Dorman DE et al. Metabolism and disposition of the antifolate LY-231514 in mice and dogs. Drug Metab. Dispos. 25(6), 693-700 (1997).
12. McDonald AC, Vasey PA. Walling J et al. Phase I and pharmacokinetic study of LY-231514, the multitargeted antifolate, administered by daily x 5 q 21 schedule. Ann. Oncol. 7, 126 (1996).
13. Rinaldi DA, Burris HA, Dorr FA et al. Initial Phase I evaluation of the novel thymidylate synthase inhibitor LY-231514, using the modified continual assessment method for dose escalation. J. Clin. Oncol. 13(11), 2842-2850 (1995).
14. Rinaldi DA, Kuhn JG, Burris HA et al. A Phase I evaluation of multitargeted antifolate (MTA, LY-231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother. Pharmacol. 44(5), 372-380 (1999).
15. Ouellet D, Periclou AP, Johnson RD, Woodworth JR, Lalonde RL. Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer. Cancer Chemother. Pharmacol. 46, 227-234 (2000).
16. Adjei AA, Erlichman C, Thornton D et al. Synergistic cytotoxicity of MTA (LY-231514) and gemcitabine in vitro and in vivo. Ann. Oncol. 9(Suppl. 2), 168 (1998) (Abstract 644).
17. Tonkinson JL, Worzalla JF, Teng CH et al. Cell cycle modulation by a multitargeted antifolate, LY-231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res. 59, 3671-3676 (1995).
18. Adjei AA, Erlichman C, Sloan JA et al. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J. Clin. Oncol. 18(8), 1748-1757 (2000).
19. Thodtmann R, Depenbrock H, Dumez H et al. Clinical and pharmacokinetic Phase I study of multitargeted antifolate (LY-231514) in combination with cisplatin. J. Clin. Oncol. 17, 3009-3016 (1999).
20. Hughes A, Calvert P, Azzabi A et al. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J. Clin. Oncol. 20(16), 3533-3544 (2002).
21. Adjei AA. Pemetrexed: a multitargeted antifolate agent with promising activity in solid tumors. Ann. Oncol. 11(10), 1335-1341 (2000).
22. Calvert AH, Walling JM. Clinical studies with MTA. Br. J. Cancer 3, 34-40 (1998).
23. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephrologie 16, 31-41 (1976).
24. Takimoto C, Baker S, Sweeney C et al. Phase I and pharmacokinetic study of pemetrexed disodium (LY-231514, MTA, ALIMTA) in patients with impaired renal function. Proc. Am. Soc. Clin. Oncol. 93A (2001) (Abstract 368).
25. Calvert H. An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents. Sem. Oncol. 26(2, Suppl. 6), 3-10 (1999).
26. Allen RH, Stabler SP, Savage DG, Lindenbaum J. Metabolic abnormalities in cobalamin (vitamin B12) and folate deficiency. FASEB J. 7, 1344-1353 (1993).
27. Snow CF. Laboratory diagnosis of vitamin B12 and folate deficiency: a guide for the primary care physician. Arc. Intern. Med. 159(12), 1289-1298 (1999).
28. Ubbink JB, van der Merwe A, Delport R et al, The effect of a subnormal vitamin B-6 status on homocysteine metabolism. J. Clin. Invest. 98(1), 177-184 (1996).
29. Stabler SP, Lindenbaum J, Savage DG et al. Elevation of serum cystathionine levels in patients with cobalamin and folate deficiency Blood 81, 3404-3413 (1993).
30. Niyikiza C, Baker SD, Seitz DE et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol. Cancer Ther. 1, 545-552 (2002).
31. Celio L, Bajetta E, Toffolatti L et al. Phase II trial of pemetrexed disodium administered every 21 days in patients with gastric cancer: efficacy and toxicity with and without folic acid. Ann. Oncol. 11(4), 65 (2000) (Abstract 284P).
32. Vogelzang NJ, Rusthoven J, Paoletti P et al. Phase III single-blinded study of pemetrexed + cisplatin versus cisplatin alone in chemonaive patients with malignant pleural mesothelioma. Proc. Am. Soc. Clin. Oncol. 21, 6 (2002) (Abstract 5).
33. John W, Picus J, Blanke C et al. Activity of multitargeted antifolate (pemetrexed disodium, LY-231514) in patients with advanced colorectal carcinoma: results from a Phase II study. Cancer 88(8), 1807-1813 (2000).
34. Cripps C, Burnell M, Jolivet J et al. Phase II study of first-line LY-231514 (multitargeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC clinical trials group study. Ann. Oncol. 10, 1175-1179 (1999).
35. Paulson R, Hainsworth J, Geyer C et al. A Phase II trial of MTA (multiple targeted antifolate, LY-231514) in patients with 5-FU and irinotecan-refractory colorectal. cancer. Proc. Am. Soc. Clin. Oncol. 1140 (1999).
36. Miller KD, Picus J, Blanke C et al. Phase II study of the multitargeted antifolate LY-231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. Ann. Oncol. 11, 101-103 (2000).
37. Rusthoven J, Eisenhauer E, Butts C et al. Multitargeted antifolate LY-231514 as first-line chemotherapy for patients with advanced nonsmall cell lung cancer: a Phase II study. J. Clin. Oncol. 17, 1194-1199 (1999).
38. Clarke SJ, Abratt R, Goedhals L, Boyer MJ, Millward MJ, Ackland SP. Phase II trial of pemetrexed disodium (ALIMTA, LY-231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Ann. Oncol. 13, 737-741 (2002).
39. Smit EF, Mattson K, von Pawel J et al. ALTIMA (pemetrexed disodium) as second-line treatment of non-small cell lung cancer: a Phase II study. Ann. Oncol. (2003) (In Press).
40. Lind MJ, Smith IE, Coleman RE et al. Phase II study of MTA (LY-231514) in patients with locally recurrent or metastatic breast cancer (LR/MBC). Proc. Am. Soc. Clin. Oncol. 17, 433a (1998).
41. Martin M, Spielmann, Namer M et al. MTA (Multitargeted Antifolate, LY-231514) in metastatic breast cancer patients with prior anthracycline exposure: a European Phase II study. Proc. Am. Soc. Clin. Oncol. 8, 427a (1999).
42. Paz-Ares L, Tabernero J, Moyano A et al. Significant activity of the multitargeted antifolate MTA (LY-231514) in advanced transitional cell carcinoma (TCC) of the bladder: results of a Phase II trial. Eur. J. Cancer 35(Suppl. 2), S81 (1999) (Abstract 160).
43. Goedhals L, van Wijk AL. MTA (LY-231514) in advanced carcinoma of the cervix. Ann. Oncol. 9, 339 (1998).
44. Llombart-Cussac A, Theodoulou M, Rowland K, Lassus M, Cruciani S. A Phase II trial of pemetrexed disodium (ALIMTA, LY-231514, MTA) in metastatic breast cancer (MBC) patients who have failed anthracyclines (A) and taxanes (T). Breast Cancer Res. Treat. 64(1), (2000) (Abstract 526).
45. O'Shaughnessy JA, Gennari A, Conte P. Pemetrexed: a promising new treatment for breast cancer. Semin. Oncol. 29(2, Suppl. 5), 36-441 (2002).
46. Scagliotti G, Shin D, Kindler H, Johnson D, Keppler U. Phase II Study of ALIMTA (pemetrexed disodium, MTA) single-agent in patients with malignant pleural mesothelioma. Eur. J. Cancer 37(6), S20-S21 (2001).
47. Pivot X, Raymond E, Laguerre B, Degardin M et al. Pemetrexed disodium in recurrent, locally advanced or metastatic squamous cell carcinoma of the head and neck. Br. J. Cancer 85(5), 649-655 (2001).
48. Ettinger DS, Monnerar C, Kelly K et al. Phase II trial of pemetrexed + gemcitabine in patients with advanced non-small cell lung cancer: importance of survival over response. Proc. Am. Soc. Clin. Oncol. 21, 8 (2002) (Abstract 1243).
49. Kindler HL, Dugan W, Hochster H, Strickland D, Jacobs A, John WJ. Clinical outcome in patients with advanced pancreatic cancer treated with pemetrexed/gemcitabine. Proc. Am. Soc. Clin. Oncol. 21, 5 (2002) (Abstract 499).
50. Adjei AA. Pemetrexed (Alimta™) and gemcitabine in the breast cancer patients previously treated with taxanes and anthracyclines. Clin. Breast Cancer 3 (Suppl. 1), 21-23 (2002).
51. Manegold C, Von Pawel J, Pirker R, Malayeri R, Blatter J, Krejcy K. Front-line treatment of advanced non-small cell lung cancer with MTA and cisplatin: a multicenter Phase II trial. Ann. Oncol. 11(4), 435-440 (2000).
52. Shepherd FA, Dancey J, Arnold A et al. Phase II study of pemetrexed disodium, a multitargeted antifolate and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma. Cancer 92(3), 595-600 (2001).
53. Clarke S, Millward M, Beale P et al. Phase I trial of pemetrexed disodium and vinorelbine (VNB) in patients with advanced malignancy. Ann. Oncol. 11(4), 140 (2000) (Abstract 641P).